Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on August 25, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). SPY072 Phase 2 SKYWAY-RA sub-study topline results disclosed for rheumatoid arthritis.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- SPY072 Phase 2 SKYWAY-RA sub-study topline results disclosed for rheumatoid arthritis
- Results cover a rheumatic-disease basket trial sub-study, making efficacy and safety data material to SPY072’s development outlook
- Press release dated August 25, 2026 contains the substantive results as Exhibit 99.1
Item 8.01 · Other Events
- SPY072 showed proof-of-mechanism in RA, but Spyre will not prioritize monotherapy advancement after results missed its internal bar
- Low dose achieved significant DAS28-CRP improvement: -1.9 versus -1.3 for placebo at Week 12
- ACR20 response reached 63% with high dose versus 43% placebo; low-dose ACR50 was 38% versus 19%
- Safety was favorable: adverse events 27% for SPY072 versus 36% placebo, with no drug-related serious TEAEs
- Upcoming catalysts include SPY003 UC data in September 2026 and SPY072 PsA/axSpA readouts in 4Q 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.